Suppr超能文献

在解读肺功能检查时使用支气管扩张剂后或支气管扩张剂前参考值的后果。

Consequences of Using Post- or Prebronchodilator Reference Values in Interpreting Spirometry.

作者信息

Malinovschi Andrei, Zhou Xingwu, Andersson Anders, Backman Helena, Bake Björn, Blomberg Anders, Caidahl Kenneth, Eriksson Maria J, Eriksson Ström Jonas, Hamrefors Viktor, Hjelmgren Ola, Janson Christer, Karimi Reza, Kylhammar David, Lindberg Anne, Lindberg Eva, Liv Per, Olin Anna-Carin, Shalabi Adel, Sköld C Magnus, Sundström Johan, Tanash Hanan, Torén Kjell, Wollmer Per, Zaigham Suneela, Östgren Carl Johan, Engvall Jan E

机构信息

Department of Medical Sciences, Clinical Physiology.

Department of Statistics.

出版信息

Am J Respir Crit Care Med. 2023 Aug 15;208(4):461-471. doi: 10.1164/rccm.202212-2341OC.

Abstract

Postbronchodilator spirometry is used for the diagnosis of chronic obstructive pulmonary disease. However, prebronchodilator reference values are used for spirometry interpretation. To compare the resulting prevalence rates of abnormal spirometry and study the consequences of using pre- or postbronchodilator reference values generated within SCAPIS (Swedish CArdioPulmonary bioImage Study) when interpreting postbronchodilator spirometry in a general population. SCAPIS reference values for postbronchodilator and prebronchodilator spirometry were based on 10,156 and 1,498 never-smoking, healthy participants, respectively. We studied the associations of abnormal spirometry, defined by using pre- or postbronchodilator reference values, with respiratory burden in the SCAPIS general population (28,851 individuals). Bronchodilation resulted in higher predicted medians and lower limits of normal (LLNs) for FEV/FVC ratios. The prevalence of postbronchodilator FEV/FVC ratio lower than the prebronchodilator LLN was 4.8%, and that of postbronchodilator FEV/FVC lower than the postbronchodilator LLN was 9.9%, for the general population. An additional 5.1% were identified as having an abnormal postbronchodilator FEV/FVC ratio, and this group had more respiratory symptoms, emphysema (13.5% vs. 4.1%;  < 0.001), and self-reported physician-diagnosed chronic obstructive pulmonary disease (2.8% vs. 0.5%,  < 0.001) than subjects with a postbronchodilator FEV/FVC ratio greater than the LLN for both pre- and postbronchodilation. Pre- and postbronchodilator spirometry reference values differ with regard to FEV/FVC ratio. Use of postbronchodilator reference values doubled the population prevalence of airflow obstruction; this was related to a higher respiratory burden. Using postbronchodilator reference values when interpreting postbronchodilator spirometry might enable the identification of individuals with mild disease and be clinically relevant.

摘要

支气管扩张剂激发后肺量计用于慢性阻塞性肺疾病的诊断。然而,支气管扩张剂激发前的参考值用于肺量计结果的解读。为了比较肺量计异常的患病率,并研究在普通人群中解读支气管扩张剂激发后肺量计时,使用瑞典心肺生物影像研究(SCAPIS)中生成的支气管扩张剂激发前或激发后的参考值所产生的影响。支气管扩张剂激发后和激发前肺量计的SCAPIS参考值分别基于10156名和1498名从不吸烟的健康参与者。我们研究了在SCAPIS普通人群(28851人)中,使用支气管扩张剂激发前或激发后的参考值定义的肺量计异常与呼吸负担之间的关联。支气管扩张导致FEV/FVC比值的预测中位数和正常下限(LLN)升高。在普通人群中,支气管扩张剂激发后FEV/FVC比值低于支气管扩张剂激发前LLN的患病率为4.8%,支气管扩张剂激发后FEV/FVC低于支气管扩张剂激发后LLN的患病率为9.9%。另外有5.1%的人被确定为支气管扩张剂激发后FEV/FVC比值异常,与支气管扩张剂激发后FEV/FVC比值高于支气管扩张剂激发前和激发后LLN的受试者相比,该组有更多的呼吸道症状、肺气肿(13.5%对4.1%;P<0.001)和自我报告的医生诊断的慢性阻塞性肺疾病(2.8%对0.5%,P<0.001)。支气管扩张剂激发前和激发后的肺量计参考值在FEV/FVC比值方面存在差异。使用支气管扩张剂激发后的参考值使气流受限的人群患病率增加了一倍;这与更高的呼吸负担有关。在解读支气管扩张剂激发后肺量计时使用支气管扩张剂激发后的参考值可能有助于识别轻度疾病患者,且具有临床意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验